Egrifta (Tesamorelin) Bone Health and Density Impact: What Women Need to Know

What Is Tesamorelin and Why Does Bone Health Matter Here?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that binds pituitary GHRH receptors and stimulates pulsatile growth-hormone (GH) secretion. The FDA approved tesamorelin as Egrifta in 2010 specifically for reducing excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy. Bone health was not the primary target, but GH and its downstream mediator insulin-like growth factor-1 (IGF-1) are among the most important anabolic signals in skeletal biology, so any drug that moves the GH-IGF-1 axis meaningfully will also move bone.

For women, this matters a great deal. Women already face accelerated bone loss at menopause, and HIV-positive women carry an additional burden: lower baseline bone mineral density (BMD), higher fracture rates, and the skeletal toxicity of certain antiretroviral drugs, particularly tenofovir disoproxil fumarate (TDF). When you add tesamorelin to that picture, the net effect on bone is not straightforward.

The GH-IGF-1 Axis and Skeletal Biology

GH acts directly on osteoblasts and indirectly through hepatic and local IGF-1 production. IGF-1 stimulates osteoblast proliferation, collagen synthesis, and mineralization. It also suppresses osteoclast apoptosis in some contexts, making the net skeletal effect of GH-axis stimulation dependent on baseline hormonal status, age, and the duration of exposure.

In adult GH deficiency, replacement therapy reliably increases lumbar spine and femoral neck BMD by roughly 1.5 to 2.5% per year over 12 months. Tesamorelin is not a GH replacement; it stimulates endogenous GH. That distinction matters because the pituitary's own regulatory feedback is preserved, which limits the degree of IGF-1 elevation and may temper both the anabolic benefit and any risk of over-suppression of bone resorption markers.

HIV-Associated Lipodystrophy and Bone: A Double Burden

HIV-associated lipodystrophy is not only a cosmetic or metabolic problem. The same disease processes that redistribute fat (elevated inflammatory cytokines, mitochondrial toxicity from older NRTIs, cortisol dysregulation) also accelerate bone resorption. Women with HIV have up to 40% higher fracture risk compared with HIV-negative women of the same age, even after adjusting for traditional osteoporosis risk factors.

The Falutz 2007 Trial: What It Showed and What It Missed

The landmark Falutz et al. NEJM 2007 trial enrolled 412 adults with HIV-associated lipodystrophy randomized to tesamorelin 2 mg/day subcutaneously or placebo for 26 weeks. The primary outcome was VAT reduction by CT scan, and tesamorelin achieved a mean 15.2% reduction versus placebo. IGF-1 levels rose significantly in the treatment arm.

What the Trial Did Not Measure

Bone density was not a prespecified outcome in Falutz 2007. The trial was powered for visceral fat change, not BMD. Women made up approximately 24% of the enrolled participants, a proportion that mirrors the chronic under-representation of women in HIV lipodystrophy trials. No sex-stratified bone data were published from this cohort.

IGF-1 as a Proxy for Bone Signal

Because Falutz 2007 measured IGF-1, and IGF-1 is a validated surrogate for osteoblast activity, the trial offers an indirect signal. Mean IGF-1 rose from baseline by approximately 66 mcg/L in the tesamorelin group at week 26, reaching levels consistent with younger-adult reference ranges. Whether that IGF-1 rise translated to measurable BMD change was not assessed. The honest answer is: we do not know from this trial alone.

Sex-Specific Physiology: How Your Hormonal Status Changes the Picture

The interaction between the GH-IGF-1 axis and female sex hormones is clinically significant and often overlooked. Estrogen upregulates GH receptor density in bone and liver, which means tesamorelin's downstream IGF-1 response is attenuated in women with low estrogen states, specifically postmenopausal women and those on aromatase inhibitors.

A framework for thinking about tesamorelin's bone impact across female life stages:

Reproductive Years (roughly ages 18 to 45, cycling)

In premenopausal women with intact ovarian function, estrogen maintains GH receptor sensitivity. Tesamorelin-driven IGF-1 rises may produce a more pronounced anabolic skeletal response compared with older women. The concern here is different: HIV-positive women of reproductive age may already have reduced BMD from ART and nutritional factors, so even a modest IGF-1 boost is unlikely to fully compensate for ongoing bone loss from TDF-containing regimens.

Bone turnover markers (serum P1NP for formation, CTX for resorption) should be checked at baseline and at 6 months in any premenopausal woman starting tesamorelin on a TDF-containing regimen.

Perimenopause (roughly ages 45 to 55, irregular cycles)

This is the window of greatest concern. Estrogen fluctuates and then falls sharply, osteoclast activity rises, and cortical bone loss accelerates. GH secretion also naturally declines with aging, and tesamorelin's pituitary stimulation may be partially blunted by reduced somatotroph responsiveness. Women in perimenopause starting tesamorelin for lipodystrophy should have a DEXA scan at baseline given the converging risks of HIV, ART toxicity, and estrogen decline.

Postmenopause

Postmenopausal women with HIV represent the group most vulnerable to compounded skeletal risk. A 2020 study in Menopause journal found that postmenopausal women with HIV had lumbar spine BMD T-scores an average of 0.8 SD lower than postmenopausal HIV-negative controls. Tesamorelin's IGF-1-mediated anabolic effect may be partially offset by estrogen deficiency reducing GH receptor signaling, meaning the net bone benefit is smaller in this group.

If tesamorelin is prescribed to a postmenopausal woman, discuss concurrent bisphosphonate therapy with her prescribing clinician if DEXA shows T-score below negative 2.5, or if she has additional fracture risk factors per the FRAX calculator.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Tesamorelin is contraindicated in pregnancy.

This is not a relative caution. The Egrifta prescribing information states the drug should be discontinued if pregnancy occurs. Tesamorelin has not been studied in pregnant women. In animal reproduction studies, tesamorelin was associated with fetal harm at exposures relevant to human dosing. IGF-1 elevation during organogenesis carries theoretical risks that have not been adequately characterized in human data.

Contraception Requirements

Any woman of reproductive potential taking tesamorelin should use reliable contraception throughout treatment. "Reliable" means a method with a typical-use failure rate below 9% per year, such as combined hormonal contraception, a progestogen-only pill taken consistently, an IUD (hormonal or copper), or a subdermal implant. Barrier methods alone are not considered reliable enough given the potential fetal risk.

If you are planning pregnancy, discuss a wash-out period with your clinician. The half-life of tesamorelin is approximately 26 minutes, so the drug clears quickly, but the downstream IGF-1 normalization timeline should inform timing of conception.

Lactation

It is not known whether tesamorelin or its metabolites transfer to human breast milk. Given the unknown risk and the fact that HIV-positive mothers in high-income settings are generally advised to avoid breastfeeding to prevent vertical transmission, tesamorelin should not be used during lactation. If a woman with HIV who is not breastfeeding requests tesamorelin postpartum, delay initiation until the postpartum period is clinically stable and viral suppression confirmed.

Bone Density Monitoring: A Practical Protocol for Women

There is no FDA-mandated bone monitoring protocol for tesamorelin. The following reflects clinical reasoning drawn from AACE osteoporosis guidelines and HIV-specific bone guidance.

Baseline Assessment

Before starting tesamorelin, obtain:

• Dual-energy X-ray absorptiometry (DEXA) of lumbar spine and total hip
• Serum 25-hydroxyvitamin D (target above 30 ng/mL in this population)
• Serum calcium and phosphate
• Bone turnover markers: P1NP (formation) and CTX (resorption) if you are on TDF or have a prior low-trauma fracture
• Hormonal status: FSH and estradiol if perimenopausal to contextualize bone risk

Monitoring Intervals

Repeat DEXA at 24 months if baseline is normal, or at 12 months if baseline T-score is below negative 1.5 or Z-score is below negative 2.0 in premenopausal women. The International Society for Clinical Densitometry recommends more frequent monitoring when multiple bone-loss risk factors coexist.

Drug Interactions That Affect Bone in Women on Tesamorelin

Several drugs commonly co-prescribed with tesamorelin in HIV-positive women interact with bone metabolism:

Tenofovir disoproxil fumarate (TDF): TDF causes proximal tubular dysfunction and phosphate wasting, which directly impairs mineralization. Women on TDF have lower BMD than those on tenofovir alafenamide (TAF) by a mean of 1 to 2% at the spine. Switching to TAF-containing regimens where possible is a reasonable bone-preservation strategy before or during tesamorelin therapy.

Glucocorticoids: Sometimes used for immune reconstitution inflammatory syndrome (IRIS) in women with HIV. Glucocorticoids suppress osteoblast function and impair GH-axis responsiveness, directly countering any bone-anabolic benefit of tesamorelin.

Progestogen-only contraception (injectable DMPA): Depot medroxyprogesterone acetate suppresses estrogen and is associated with BMD loss of 2 to 6% per year at the spine in premenopausal women. Women on DMPA and tesamorelin simultaneously carry compounded skeletal risk. Consider switching to a non-DMPA contraceptive method.

Protease inhibitors: Some older protease inhibitors, particularly ritonavir-boosted regimens, increase cytochrome P450 3A4 activity and may alter cortisol metabolism, indirectly affecting bone. Tesamorelin does not appear to have major CYP interactions, but the co-prescription context matters.

Female-Relevant Conditions Intersecting With Tesamorelin Use

PCOS

Women with polycystic ovary syndrome who are HIV-positive present an unusual phenotype. PCOS is associated with higher androgen levels, which can be modestly protective for bone, but also insulin resistance and chronic low-grade inflammation, which are harmful. The GH axis in PCOS is often dysregulated with blunted GH pulsatility. Whether tesamorelin's pituitary stimulation normalizes GH pulsatility differently in PCOS is not established. Extrapolating from GH deficiency studies is speculative; this is a genuine evidence gap.

Premature Ovarian Insufficiency

Women with HIV who develop premature ovarian insufficiency (POI) before age 40, from any cause, face estrogen deficiency at an age when bone accrual should still be occurring. POI itself carries a high fracture risk. If tesamorelin is considered in a woman with POI, concurrent hormone therapy is strongly recommended per ACOG guidance on POI to maintain BMD, independent of the lipodystrophy indication.

Female Pattern Metabolic Disease and Lipodystrophy

HIV-associated lipodystrophy in women often presents differently than in men: more peripheral fat loss (from the face, buttocks, and limbs) and less visceral fat accumulation. The visceral fat reduction that tesamorelin produces may be less visible or clinically dramatic in women, and the Falutz 2007 trial enrolled predominantly men, so the magnitude of VAT response in women specifically is less certain. The bone-relevant metabolic improvements (reduced inflammatory cytokines, improved insulin sensitivity) that accompany fat reduction may indirectly benefit bone, but this has not been quantified in female-specific analyses.

Who Is a Reasonable Candidate for Tesamorelin, and Who Should Be Cautious

Women Likely to Benefit

• HIV-positive women with confirmed visceral lipodystrophy on DEXA or CT
• Women with pre-existing low-normal BMD who are on TAF (not TDF) and maintain good vitamin D status
• Premenopausal women with intact ovarian function and no contraindication to IGF-1 elevation
• Women whose metabolic profile shows elevated triglycerides alongside visceral fat, since tesamorelin also reduces triglycerides by approximately 50 mg/dL in lipodystrophy trials

Women Who Need Extra Caution or Are Not Good Candidates

• Women planning pregnancy within the next 12 months
• Postmenopausal women with T-score below negative 2.5 who have not yet tried antiresorptive therapy
• Women on DMPA with no plan to switch contraceptive methods
• Women with active malignancy (IGF-1 elevation is a concern in hormone-sensitive cancers, though direct evidence of tesamorelin-driven cancer promotion is not established)
• Women with diabetic retinopathy, since IGF-1 elevation can worsen retinal neovascularization; this is a labeled warning in the Egrifta prescribing information
• Women with known pituitary disease or prior pituitary irradiation, where the GHRH-receptor response is compromised

The Evidence Gap: What We Still Do Not Know About Women

Clinician commentary from WomanRx editorial board member Elena Vasquez, MD: "The honest reality is that every bone-specific inference we make about tesamorelin in women is extrapolated from GH-axis physiology, adult GH deficiency replacement data, and trials where women were a minority. We do not have a single adequately powered, sex-stratified trial examining BMD change as a primary outcome in women with HIV-associated lipodystrophy on tesamorelin. Until that trial exists, we are making educated clinical judgments, not evidence-based recommendations."

This gap is not unique to tesamorelin. A 2023 NIH analysis found that women represented fewer than 30% of participants in HIV metabolic complication trials published between 2000 and 2022, and that sex-disaggregated outcome reporting occurred in fewer than 40% of those trials. Bone endpoints were among the least frequently sex-stratified outcomes.

What we need, and do not yet have:

• A 24-month, DEXA-powered, sex-stratified trial of tesamorelin 2 mg/day versus placebo in women with HIV-associated lipodystrophy, with BMD at lumbar spine, total hip, and femoral neck as co-primary outcomes
• Serum P1NP and CTX measurements at 6, 12, and 24 months to track bone turnover direction
• Subgroup analyses by menopausal status, ART regimen (TDF vs. TAF), and hormonal contraception use
• Data on tesamorelin use in women with concurrent hormone therapy for menopause or POI

Until that evidence exists, clinical decisions must be made transparently, with shared decision-making that acknowledges the extrapolation.

Practical Steps at Your Next Appointment

If you are HIV-positive, have been diagnosed with lipodystrophy, and your clinician is discussing tesamorelin:

1. Ask for a baseline DEXA scan before your first injection, specifically requesting lumbar spine and total hip measurements.
2. Ask for a serum 25-hydroxyvitamin D level and start supplementation to reach above 30 ng/mL.
3. Confirm your ART regimen: if you are on TDF, ask whether TAF is an appropriate switch for your viral situation.
4. Discuss your contraceptive plan explicitly. If you are on DMPA, ask whether an IUD or implant would serve you better given the compounded bone risk.
5. If you are perimenopausal or postmenopausal, ask your clinician to calculate your FRAX 10-year fracture probability before deciding whether tesamorelin's potential bone-anabolic signal outweighs other interventions like bisphosphonates.
6. Set a 12-month bone turnover marker check if you have any elevated-risk features listed above.

Your DEXA T-score at the femoral neck is the single number that most changes the risk-benefit discussion for tesamorelin in the context of bone health. A T-score above negative 1.0 with good vitamin D status and TAF-based ART is a substantially different starting point than a T-score of negative 2.3 on TDF with DMPA contraception.